Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tianenfu + Chemoradiotherapy in Locally Advanced NPC
NCT05433597Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2022
- Primary completion
- Jul 2024
- Modality
- Cytokines & Interferons
01
Overview
Phase 3, randomised, double-blind trial of rmhTNF-NC in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoints: Overall Survival at 5 years, Progression-Free Survival at 5 years and 1 more. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
rmhTNF-NC
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05433597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05433597.